Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ovarian Stimulation: Inositol and Melatonin
NCT01267604 · AGUNCO Obstetrics and Gynecology Centre · PHASE4 · withdrawn · last registry update 2023-07-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, AGUNCO Obstetrics and Gynecology Centre |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FSHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-05Phase 3 first posted: Cairo University, Gonadotropin + Letrozole (NCT06486870)
- 2024-06-17Also stopped (terminated): Organon and Co, corifollitropin alfa + recombinant Follicle Stimulating Hormone (recFSH) (NCT00697255)
- 2024-05-22Also stopped (terminated): Fundacion Dexeus, Testosterone gel + Placebo gel (NCT02418572)
- 2024-05-17Phase 3 first posted: Ain Shams University, Alpha lipoic acid + Letrozole (NCT06418347)
- 2024-05-13Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + GnRH agonist (GONAPEPTYL) + FE 999049 + GnRH antagonist (CETROTIDE) (NCT03809429)
- 2024-02-28Also stopped (withdrawn): CRG UZ Brussel, Lutropin alfa + Follitropin alfa (NCT05405686)
- 2024-01-29Phase 3 first posted: Ellen Greenblatt, Luveris (NCT06227949)
- 2024-01-26Also stopped (withdrawn): Clínica EUGIN, a drug against FSHR (NCT05948293)
- 2024-01-18Results posted on the registry: Ferring Pharmaceuticals, Follitropin delta (NCT03740737)
- 2024-01-18Results posted on the registry: Ferring Pharmaceuticals, Follitropin delta + Placebo (NCT03738618)
- 2024-01-10Phase 3 first posted: Royan Institute, a drug against FSHR (NCT06199960)
- 2023-12-18Phase 3 first posted: Ferring Pharmaceuticals, FE 999049 + GONAL-F (NCT06173869)
- 2023-11-18Phase 3 first posted: Fundación Santiago Dexeus Font, 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5 + 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger (NCT06134479)
- 2023-11-07Results posted on the registry: Ferring Pharmaceuticals, MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL + MENOPUR powder and solvent for solution for injection, 75 IU (NCT04163458)
- 2023-10-19Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., GenSci094 + Placebo RecFSH / follitropin alfa (NCT06091436)
- 2023-09-21Phase 3 first posted: Beni-Suef University, Intra ovarian by platelet rich plasma (NCT06048666)
- 2023-08-24Also stopped (terminated): Institut Curie, a drug against FSHR (NCT02860481)
- 2022-11-30Also stopped (withdrawn): Assiut University, Letrozole + Menotropins (NCT04193930)
- 2022-08-11Also stopped (terminated): IVI Madrid, Corifollitropin alfa (NCT02402192)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision